Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
526
NCT03606395
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 6, 2018
Completion: Jul 7, 2019
NCT05152680
Mass Balance Study of NV-5138 in Healthy Male Subjects.
Start: Nov 11, 2021
Completion: Dec 9, 2021
NCT05066672
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Phase: Phase 2
Start: Feb 28, 2022
Completion: Feb 15, 2025
NCT06235905
Open-Label of SPN-820 in Adults With Major Depressive Disorder
Start: Feb 15, 2024
Completion: Aug 18, 2024